Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.
This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute Coronary Syndrome | Patient with acute coronary syndrome due to atherosclerotic coronary artery disease | ||
| Chronic coronary syndrome | Patient with chronic coronary syndrome due to atherosclerotic coronary artery disease |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Low-density lipoprotein cholesterol (LDL-C) level | Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline | Baseline |
| Low-density lipoprotein cholesterol (LDL-C) level | Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8 | week 8 |
| Low-density lipoprotein cholesterol (LDL-C) level | Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26 | Week 26 |
| Low-density lipoprotein cholesterol (LDL-C) level | Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52 | Week 52 |
| Low-density lipoprotein cholesterol (LDL-C) level | Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline | Baseline |
| Low-density lipoprotein cholesterol (LDL-C) level | Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8 | Week 8 |
| Low-density lipoprotein cholesterol (LDL-C) level | Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26 | Week 26 |
| Low-density lipoprotein cholesterol (LDL-C) level |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of subject meeting LDL-C target | Proportion of patients meeting prespecified LDL-C goals (>50% reduction from baseline) at week 26. | Week 26 |
| Rate of subject meeting LDL-C target | Proportion of patients meeting prespecified LDL-C goals (<1.4mmol/l) at week 26. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients aged greater than 18 and who are admitted for a diagnosis of acute coronary syndrome (ACS) due to atherosclerotic coronary artery disease based on invasive coronary angiography will be recruited into this registry.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guangming Tan | Contact | 852-35051518 | xjldaniel@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prince of Wales Hospital | Recruiting | Shatin | New Terrritories | 999077 | Hong Kong |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52 |
| Week 52 |
| Week 26 |
| Rate of subject meeting LDL-C target | Proportion of patients meeting prespecified LDL-C goals (<1.8mmol/L) at week 26. | Week 26 |
| 12-Item Short Form Survey (SF-12) | Patient's quality of life as measured by SF-12 at baseline | Baseline |
| 12-Item Short Form Survey (SF-12) | Patient's quality of life as measured by SF-12 at week 8 | Week 8 |
| 12-Item Short Form Survey (SF-12) | Patient's quality of life as measured by SF-12 at week 26 | Week 26 |
| 12-Item Short Form Survey (SF-12) | Patient's quality of life as measured by SF-12 at week 52 | Week 52 |
| Rate of major adverse cardiovascular event (MACE) | Occurrence of any major adverse cardiovascular event (MACE) at Baseline | Baseline |
| Rate of major adverse cardiovascular event (MACE) | Occurrence of any major adverse cardiovascular event (MACE) at week 8 | Week 8 |
| Rate of major adverse cardiovascular event (MACE) | Occurrence of any major adverse cardiovascular event (MACE) at week 26 | Week 26 |
| Rate of major adverse cardiovascular event (MACE) | Occurrence of any major adverse cardiovascular event (MACE) at week 52 | Week52 |
| Modification of lipid lowering therapy (LLT) | Modification of lipid lowering therapy (LLT) at week 8 | Week 8 |
| Modification of lipid lowering therapy (LLT) | Modification of lipid lowering therapy (LLT) at week 26 | Week 26 |
| Modification of lipid lowering therapy (LLT) | Modification of lipid lowering therapy (LLT) at week 52 | Week 52 |
| Lipid Lowering Therapy adherence | LLT adherence, expressed in proportion of days covered, at week 52 | Week 52 |
| Tolerability of Lipid Lowering Therapy | Rate of adverse drug event reported by subjects on lipid lowering therapy at week 52 | Week 52 |